Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 4/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885089 | 0.95 | DNM1 (0.33) | DNM1OPRM1ACE2ALDH1A1TDP1 | |
| SCHEMBL1971842 | 0.92 | OPRM1 (0.44) | DNM1OPRM1ACE2LMNATSHR | |
| SCHEMBL5084014 | 0.90 | ACE2 (0.45) | DNM1OPRM1ACE2LMNATSHR | |
| SCHEMBL5085923 | 0.90 | ACE2 (0.45) | DNM1OPRM1ACE2LMNATSHR | |
| SCHEMBL10937533 | 0.90 | ACE2 (0.45) | DNM1OPRM1ACE2LMNATSHR | |
| SCHEMBL3366905 | 0.90 | ACE2 (0.45) | DNM1OPRM1ACE2LMNATSHR | |
| SCHEMBL2761289 | 0.90 | ACE2 (0.45) | DNM1OPRM1ACE2LMNATSHR | |
| SCHEMBL5085904 | 0.90 | ACE2 (0.45) | DNM1OPRM1ACE2LMNATSHR | |
| SCHEMBL11096927 | 0.90 | ACE2 (0.45) | DNM1OPRM1ACE2LMNATSHR | |
| SCHEMBL1969416 | 0.90 | ACE2 (0.45) | DNM1OPRM1ACE2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117986215-A | 2-Phenyl-4-acyl benzofurans, preparation and application thereof | 中国医学科学院药物研究所 | 2024-05-07 | — | — | CN | claimed |
| CN-116693479-A | BysspinA derivative, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2023-09-05 | — | — | CN | claimed |
| CN-117986215-A | 2-Phenyl-4-acyl benzofurans, preparation and application thereof | 中国医学科学院药物研究所 | 2024-05-07 | — | — | CN | disclosed |
| CN-111372916-B | Process for producing dipyrrolidine compounds | 巴斯夫欧洲公司 | 2024-03-26 | — | — | CN | disclosed |
| WO-2023182221-A1 | METHOD FOR PRODUCING QUANTUM DOTS | 日本化学工業株式会社 | 2023-09-28 | — | — | WO | disclosed |
| CN-116693479-A | BysspinA derivative, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2023-09-05 | — | — | CN | disclosed |
| CN-112480938-B | Negative dielectric anisotropy liquid crystal composition and liquid crystal display device | 烟台显华化工科技有限公司 | 2022-09-27 | — | — | CN | disclosed |
| US-11345680-B2 | Method for producing bispyrrolidine compounds | BASF SE (DE) | 2022-05-31 | — | — | US | disclosed |
| CN-112480938-A | Negative dielectric anisotropy liquid crystal composition and liquid crystal display device | 烟台显华化工科技有限公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200392115-A1 | METHOD FOR PRODUCING BISPYRROLIDINE COMPOUNDS | BASF SE (DE) | 2020-12-17 | — | — | US | disclosed |
| EP-3713915-A1 | METHOD FOR PRODUCING BISPYRROLIDINE COMPOUNDS | BASF SE (DE) | 2020-09-30 | — | — | EP | disclosed |
| EP-0693284-A1 | PROSTACYCLIN-CONTAINING OLEAGINOUS OINTMENT | TEIJIN LIMITED (JP) | 1996-01-24 | — | — | EP | disclosed |
| US-4317818-A | 3,17-DIOXOANDROST-4-EN-19-AL AND DERIVATIVES | RICHARDSON-MERRELL INC. (US) | 1982-03-02 | — | — | US | disclosed |
| US-4096254-A | STEROIDS | RICHARDSON-MERRELL INC. (US) | 1978-06-20 | — | — | US | disclosed |
| US-4088760-A | TREATMENT OF ACNE AND OILY SKIN | RICHARDSON-MERRELL INC. (US) | 1978-05-09 | — | — | US | disclosed |
| US-4078060-A | ANDROSTENONES | RICHARDSON-MERRELL INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4078061-A | ANDROSTENONES | RICHARDSON-MERRELL INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4055641-A | STEROID, 3-OXO-ANDROST-4-ENES | RICHARDSON-MERRELL INC. (US) | 1977-10-25 | — | — | US | disclosed |
| US-4054651-A | Method of contraception | RICHARDSON-MERRELL INC. (US) | 1977-10-18 | — | — | US | disclosed |
| US-4013762-A | STEROIDS WITHOUT ANDROGENIZING EFFECT | RICHARDSON-MERRELL INC. (US) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392115-A1 | METHOD FOR PRODUCING BISPYRROLIDINE COMPOUNDS | BBOX1, DHPS, BCKDK | DNM1 2909/4885OPRM1 1005/4885ACE2 1793/4885 |
| US-11345680-B2 | Method for producing bispyrrolidine compounds | BCKDK, BBOX1, DHPS | DNM1 2924/4885OPRM1 875/4885ACE2 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.